Blood Cancer Journal (May 2022)

Structural variants shape the genomic landscape and clinical outcome of multiple myeloma

  • Cody Ashby,
  • Eileen M. Boyle,
  • Michael A. Bauer,
  • Aneta Mikulasova,
  • Christopher P. Wardell,
  • Louis Williams,
  • Ariel Siegel,
  • Patrick Blaney,
  • Marc Braunstein,
  • David Kaminetsky,
  • Jonathan Keats,
  • Francesco Maura,
  • Ola Landgren,
  • Brian A. Walker,
  • Faith E. Davies,
  • Gareth J. Morgan

DOI
https://doi.org/10.1038/s41408-022-00673-x
Journal volume & issue
Vol. 12, no. 5
pp. 1 – 9

Abstract

Read online

Abstract Deciphering genomic architecture is key to identifying novel disease drivers and understanding the mechanisms underlying myeloma initiation and progression. In this work, using the CoMMpass dataset, we show that structural variants (SV) occur in a nonrandom fashion throughout the genome with an increased frequency in the t(4;14), RB1, or TP53 mutated cases and reduced frequency in t(11;14) cases. By mapping sites of chromosomal rearrangements to topologically associated domains and identifying significantly upregulated genes by RNAseq we identify both predicted and novel putative driver genes. These data highlight the heterogeneity of transcriptional dysregulation occurring as a consequence of both the canonical and novel structural variants. Further, it shows that the complex rearrangements chromoplexy, chromothripsis and templated insertions are common in MM with each variant having its own distinct frequency and impact on clinical outcome. Chromothripsis is associated with a significant independent negative impact on clinical outcome in newly diagnosed cases consistent with its use alongside other clinical and genetic risk factors to identify prognosis.